Advertisement

Risks and benefits of reducing target volume margins in breast tangent radiotherapy

  • Deepak BasaulaEmail author
  • Alexandra Quinn
  • Amy Walker
  • Vikneswary Batumalai
  • Shivani Kumar
  • Geoff P. Delaney
  • Lois Holloway
Scientific Paper

Abstract

This study investigates the potential benefits of planning target volume (PTV) margin reduction for whole breast radiotherapy in relation to dose received by organs at risk (OARs), as well as reductions in radiation-induced secondary cancer risk. Such benefits were compared to the increased radiation-induced secondary cancer risk attributed from increased ionizing radiation imaging doses. Ten retrospective patients’ computed tomography datasets were considered. Three computerized treatment plans with varied PTV margins (0, 5 and 10 mm) were created for each patient complying with the Radiation Therapy Oncology Group (RTOG) 1005 protocol requirements. The BEIR VII lifetime attributable risk (LAR) model was used to estimate secondary cancer risk to OARs. The LAR was assessed for all treatment plans considering (a) doses from PTV margin variation and (b) doses from two (daily and weekly) kilovoltage cone beam computed tomography (kV CBCT) imaging protocols during the course of treatment. We found PTV margins from largest to smallest resulted in a mean OAR relative dose reduction of 31% (heart), 28% (lung) and 23% (contralateral breast) and the risk of radiation-induced secondary cancer by a relative 23% (contralateral breast) and 22% (contralateral lung). Daily image-guidance using kV CBCT increased the risk of radiation induced secondary cancer to the contralateral breast and contralateral lung by a relative 1.6–1.9% and 1.9–2.5% respectively. Despite the additional dose from kV CBCT for the two considered imaging protocols, smaller PTV margins would still result in an overall reduction in secondary cancer risk.

Keywords

Breast radiotherapy Planning target volume Margin Secondary cancer risk Imaging dose 

Notes

Acknowledgements

This work is supported by Cancer Australia and The National Breast Cancer Foundation Grant Project Number 1033237.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

The ethics was approved by the local institutional ethics board.

References

  1. 1.
    Flannery TW, Nichols EM, Cheston SB, Marter KJ, Naqvi SA, Markham KM, Ali I, Mohiuddin MM (2009) Repeat computed tomography simulation to assess lumpectomy cavity volume during whole-breast irradiation. Int J Radiat Oncol Biol Phys 75(3):751–756CrossRefPubMedGoogle Scholar
  2. 2.
    International Commission of Radiation Units and Measurements (ICRU) Prescribing, recording and reporting photon beam therapy (supplement to ICRU report 50) (1999). ICRU report 62Google Scholar
  3. 3.
    Darby SC, Ewertz M, McGale P, Bennet AM, Blom-Goldman U, Brønnum D, Correa C, Cutter D, Gagliardi G, Gigante B (2013) Risk of ischemic heart disease in women after radiotherapy for breast cancer. N Engl J Med 368(11):987–998CrossRefPubMedGoogle Scholar
  4. 4.
    Marks LB, Bentzen SM, Deasy JO, Kong F-MS, Bradley JD, Vogelius IS, El Naqa I, Hubbs JL, Lebesque JV, Timmerman RD (2010) Radiation dose–volume effects in the lung. Int J Radiat Oncol Biol Phys 76(3):S70–S76CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Gagliardi G, Constine LS, Moiseenko V, Correa C, Pierce LJ, Allen AM, Marks LB (2010) Radiation dose–volume effects in the heart. Int J Radiat Oncol Biol Phys 76(3):S77–S85CrossRefPubMedGoogle Scholar
  6. 6.
    Kwa SL, Lebesque JV, Theuws JC, Marks LB, Munley MT, Bentel G, Oetzel D, Spahn U, Graham MV, Drzymala RE (1998) Radiation pneumonitis as a function of mean lung dose: an analysis of pooled data of 540 patients. Int J Radiat Oncol Biol Phys 42(1):1–9CrossRefPubMedGoogle Scholar
  7. 7.
    Hurkmans CW, Borger JH, Bos LJ, van der Horst A, Pieters BR, Lebesque JV, Mijnheer BJ (2000) Cardiac and lung complication probabilities after breast cancer irradiation. Radiat Oncol 55(2):145–151CrossRefGoogle Scholar
  8. 8.
    Lemanski C, Thariat J, Ampil FL, Bose S, Vock J, Davis R, Chi A, Dutta S, Woods W, Desai A (2014) Image-guided radiotherapy for cardiac sparing in patients with left-sided breast cancer. Front Oncol 4:257 doi: 10.3389/fonc.2014.00257 CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Donovan E, Castellano I, Eagle S, Harris E (2012) Clinical implementation of kilovoltage cone beam CT for the verification of sequential and integrated photon boost treatments for breast cancer patients. Br J Radiol 85(1019):e1051–e1057CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Kim LH, DeCesare S, Vicini F, Yan D (2010) Effect of lumpectomy cavity volume change on the clinical target volume for accelerated partial breast irradiation: a deformable registration study. Int J Radiat Oncol Biol Phys 78(4):1121–1126CrossRefPubMedGoogle Scholar
  11. 11.
    van Loon J, Siedschlag C, Stroom J, Blauwgeers H, van Suylen R-J, Knegjens J, Rossi M, van Baardwijk A, Boersma L, Klomp H (2012) Microscopic disease extension in three dimensions for non–small-cell lung cancer: development of a prediction model using pathology-validated positron emission tomography and computed tomography features. Int J Radiat Oncol Biol Phys 82(1):448–456CrossRefPubMedGoogle Scholar
  12. 12.
    Van Herk M (2007) Different styles of image-guided radiotherapy. In: Semin Radiat Oncol. Vol 4. Elsevier, pp 258–267Google Scholar
  13. 13.
    Schnitt SJ, Abner A, Gelman R, Connolly JL, Recht A, Duda RB, Eberlein TJ, Mayzel K, Silver B, Harris JR (1994) The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy. Cancer 74(6):1746–1751CrossRefPubMedGoogle Scholar
  14. 14.
    De Gonzalez AB, Curtis R, Gilbert E, Berg C, Smith S, Stovall M, Ron E (2010) Second solid cancers after radiotherapy for breast cancer in SEER cancer registries. Br J Cancer 102(1):220–226CrossRefGoogle Scholar
  15. 15.
    Quinn A, Holloway L, Begg J, Nelson V, Metcalfe P (2014) Kilovoltage cone-beam CT imaging dose during breast radiotherapy: a dose comparison between a left and right breast setup. Med Dosim 39(2):190–193CrossRefPubMedGoogle Scholar
  16. 16.
    Spezi E, Downes P, Jarvis R, Radu E, Staffurth J (2012) Patient-specific three-dimensional concomitant dose from cone beam computed tomography exposure in image-guided radiotherapy. Int J Radiat Oncol Biol Phys 83(1):419–426CrossRefPubMedGoogle Scholar
  17. 17.
    Donovan E, James H, Bonora M, Yarnold J, Evans P (2012) Second cancer incidence risk estimates using BEIR VII models for standard and complex external beam radiotherapy for early breast cancer. Med Phys 39(10):5814–5824CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Quinn A, Holloway L, Hardcastle N, Tomé WA, Rosenfeld A, Metcalfe P (2013) Normal tissue dose and second cancer risk due to megavoltage fan-beam CT, static tomotherapy and helical tomotherapy in breast radiotherapy. Radiat Oncol 108(2):266–268CrossRefGoogle Scholar
  19. 19.
    Kim DW, Chung WK, Yoon M (2013) Imaging doses and secondary cancer risk from kilovoltage cone-beam CT in radiation therapy. Health Phys 104(5):499–503CrossRefPubMedGoogle Scholar
  20. 20.
    Santos AM, Marcu LG, Wong CM, Bezak E (2016) Risk estimation of second primary cancers after breast radiotherapy. Acta Oncologica 1–7Google Scholar
  21. 21.
    Van der Laan HP, Hurkmans CW, Kuten A, Westenberg HA (2010) Current technological clinical practice in breast radiotherapy; results of a survey in EORTC-Radiation Oncology Group affiliated institutions. Radiother Oncol 94(3):280–285CrossRefPubMedGoogle Scholar
  22. 22.
    Vicini F, Freedman G, White J, Arthur D, Hayman J, Rosenstein B, Bentzen S, Li X, Halyard M, Taghian A, Bleicher R, Winter K (2012) Availabe from: http://www.rtog.org/ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=1005 RTOG 1005: A phase III trial of accelerated whole breast irradiation with hypofractionation plus concurrent boost versus standard whole breast irradiation plus sequential boost for early-stage breast cancer. National Cancer Institute
  23. 23.
    Niemierko A (1997) Reporting and analyzing dose distributions: a concept of equivalent uniform dose. Med Phys 24(1):103–110CrossRefPubMedGoogle Scholar
  24. 24.
    Gay HA, Niemierko A (2007) A free program for calculating EUD-based NTCP and TCP in external beam radiotherapy. Phys Medica 23(3):115–125CrossRefGoogle Scholar
  25. 25.
    Wu Q, Mohan R, Niemierko A, Schmidt-Ullrich R (2002) Optimization of intensity-modulated radiotherapy plans based on the equivalent uniform dose. Int J Radiat Oncol Biol Phys 52(1):224–235CrossRefPubMedGoogle Scholar
  26. 26.
    Li XA, Alber M, Deasy JO, Jackson A, Jee K-WK, Marks LB, Martel MK, Mayo C, Moiseenko V, Nahum AE (2012) The use and QA of biologically related models for treatment planning: Short report of the TG-166 of the therapy physics committee of the AAPMa. Med Phys 39(3):1386–1409CrossRefGoogle Scholar
  27. 27.
    Emami B, Lyman J, Brown A, Cola L, Goitein M, Munzenrider J, Shank B, Solin L, Wesson M (1991) Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys 21(1):109–122CrossRefPubMedGoogle Scholar
  28. 28.
    Alexander M, Brooks W, Blake S (2007) Normal tissue complication probability modelling of tissue fibrosis following breast radiotherapy. Phys Med Biol 52(7):1831CrossRefPubMedGoogle Scholar
  29. 29.
    BEIR VII PHASE II (2006) Health risks from exposure to low levels of ionizing radiation. The National Academies Press, Washington DCGoogle Scholar
  30. 30.
    Nguyen J, Moteabbed M, Paganetti H (2015) Assessment of uncertainties in radiation-induced cancer risk predictions at clinically relevant doses. Med Phys 42(1):81–89CrossRefPubMedGoogle Scholar
  31. 31.
    Schneider U, Lomax A, Besserer J, Pemler P, Lombriser N, Kaser-Hotz B (2007) The impact of dose escalation on secondary cancer risk after radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys 68(3):892–897CrossRefPubMedGoogle Scholar
  32. 32.
    Jacob J, Heymann S, Borget I, Dumas I, Riahi E, Maroun P, Ezra P, Roberti E, Rivera S, Deutsch E (2015) Dosimetric effects of the interfraction variations during whole breast radiotherapy: a prospective study. Front Oncol 5:199CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Chi F, Wu S, Zhou J, Li F, Sun J, Lin Q, Lin H, Guan X, He Z (2015) Dosimetric comparison of moderate deep inspiration breath-hold and free-breathing intensity-modulated radiotherapy for left-sided breast cancer. Cancer/Radiothérapie 19(3):180–186CrossRefGoogle Scholar
  34. 34.
    Edvardsson A, Nilsson MP, Amptoulach S, Ceberg S (2015) Comparison of doses and NTCP to risk organs with enhanced inspiration gating and free breathing for left-sided breast cancer radiotherapy using the AAA algorithm. Radiat Oncol 10(1):84CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Collette S, Collette L, Budiharto T, Horiot J-C, Poortmans PM, Struikmans H, Van den Bogaert W, Fourquet A, Jager JJ, Hoogenraad W (2008) Predictors of the risk of fibrosis at 10 years after breast conserving therapy for early breast cancer: a study based on the EORTC trial 22881–10882 ‘boost versus no boost’. Eur J Cancer 44(17):2587–2599CrossRefPubMedGoogle Scholar
  36. 36.
    Mukesh MB, Harris E, Collette S, Coles CE, Bartelink H, Wilkinson J, Evans PM, Graham P, Haviland J, Poortmans P (2013) Normal tissue complication probability (NTCP) parameters for breast fibrosis: pooled results from two randomised trials. Radiother Oncol 108(2):293–298CrossRefPubMedGoogle Scholar
  37. 37.
    Taylor C, Kirby A (2015) Cardiac side-effects from breast cancer radiotherapy. Clin Oncol 27(11):621–629CrossRefGoogle Scholar
  38. 38.
    Witte MG, van der Geer J, Schneider C, Lebesque JV, Alber M, van Herk M (2007) IMRT optimization including random and systematic geometric errors based on the expectation of TCP and NTCP. Med Phys 34(9):3544–3555CrossRefPubMedGoogle Scholar
  39. 39.
    Baum C, Alber M, Birkner M, Nüsslin F (2006) Robust treatment planning for intensity modulated radiotherapy of prostate cancer based on coverage probabilities. Radiother Oncol 78(1):27–35CrossRefPubMedGoogle Scholar
  40. 40.
    Wiant DB, Wentworth S, Maurer JM, Vanderstraeten CL, Terrell JA, Sintay BJ (2014) Surface imaging-based analysis of intrafraction motion for breast radiotherapy patients. J Appl Clin Med Phys 15(6)Google Scholar
  41. 41.
    Murray L, Sethugavalar B, Robertshaw H, Bayman E, Thomas E, Gilson D, Prestwich R (2015) Involved node, site, field and residual volume radiotherapy for lymphoma: a comparison of organ at risk dosimetry and second malignancy risks. Clin Oncol 27(7):401–410. doi: 10.1016/j.clon.2015.03.005 CrossRefGoogle Scholar
  42. 42.
    Coles C, Agrawal R, Ah-See M, Algurafi H, Alhasso A, Brunt A, Chan C, Griffin C, Harnett A, Hopwood P (2016) Partial breast radiotherapy for women with early breast cancer: first results of local recurrence data for IMPORT LOW (CRUK/06/003). In: EUR J CANCER, 2016. ELSEVIER SCI LTD THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND, pp S4–S4Google Scholar
  43. 43.
    Stroom J, Schlief A, Alderliesten T, Peterse H, Bartelink H, Gilhuijs K (2009) Using histopathology breast cancer data to reduce clinical target volume margins at radiotherapy. Int J Radiat Oncol Biol Phys 74(3):898–905CrossRefPubMedGoogle Scholar
  44. 44.
    Selvaraj J, Uzan J, Baker C, Nahum A (2013) Loss of local control due to tumour displacement as a function of margin size, dose–response slope, and number of fractions. Med Phys 40(4):041715CrossRefPubMedGoogle Scholar
  45. 45.
    Stroom JC, de Boer HC, Huizenga H, Visser AG (1999) Inclusion of geometrical uncertainties in radiotherapy treatment planning by means of coverage probability. Int J Radiat Oncol Biol Phys 43(4):905–919CrossRefPubMedGoogle Scholar
  46. 46.
    Stroom JC, Heijmen BJ (2002) Geometrical uncertainties, radiotherapy planning margins, and the ICRU-62 report. Radiat Oncol 64(1):75–83CrossRefGoogle Scholar
  47. 47.
    Stroom J, Gilhuijs K, Vieira S, Chen W, Salguero J, Moser E, Sonke J-J (2014) Combined recipe for clinical target volume and planning target volume margins. Int J Radiat Oncol Biol Phys 88(3):708–714CrossRefPubMedGoogle Scholar
  48. 48.
    van Herk M, Remeijer P, Rasch C, Lebesque JV (2000) The probability of correct target dosage: dose-population histograms for deriving treatment margins in radiotherapy. Int J Radiat Oncol Biol Phys 47(4):1121–1135CrossRefPubMedGoogle Scholar

Copyright information

© Australasian College of Physical Scientists and Engineers in Medicine 2017

Authors and Affiliations

  1. 1.Department of Medical Physics and Radiation EngineeringThe Canberra HospitalGarranAustralia
  2. 2.Northern Sydney Cancer Therapy CentreRoyal North Shore HospitalSydneyAustralia
  3. 3.Liverpool and Macarthur Cancer Therapy CentresSydneyAustralia
  4. 4.Ingham Institute of Applied Medical ResearchSydneyAustralia
  5. 5.University of New South WalesSydneyAustralia
  6. 6.Centre for Medical Radiation PhysicsUniversity of WollongongWollongongAustralia
  7. 7.Institute of Medical PhysicsUniversity of SydneySydneyAustralia

Personalised recommendations